NICE Finally Recommends Alzheimer's Therapies For Mild Disease

New clinical data lead U.K.'s cost regulator to recommend expanded reimbursement for Aricept, Exelon and Reminyl among patients with mild Alzheimer's disease, and for Exiba in moderate disease.